Search results for "Regurgitation"
showing 10 items of 102 documents
Pacing ventricolare destro: una risorsa o una minaccia?
2005
Early after the beginning of the pacemaker era, endocardial right ventricular apex has been the most extensively used site for cardiac pacing because it was easily accessible and reliable in a long-term perspective. However many data have demonstrated that this kind of pacing is suboptimal from a physiologic point of view because it causes several adverse effects such as altered ventricular contraction geometry, mitral regurgitation, perfusion alterations and interference with myocardial ion channels which determine a worsening of left ventricular function. Several strategies have been proposed to solve these problems (alternative pacing sites, specific algorithms able to reduce the percent…
The importance of being “not transplantable”
2017
Quantitative Bestimmung des Gallenr�ckflusses in Blut und Leberlymphe von Ratten bei beginnender Gallenstauung
1970
1. Mit dem Ziel, die Anteile des bei einer Gallenstauung auftretenden Gallenruckflusses in Blut und Lymphe quantitativ zu erfassen, wurde ein Verfahren zur Gewinnung reiner Leberlymphe bei Ratten entwickelt. 2. Mit Hilfe dieser Methode konnte am Versuchstier mit normaler Korpertemperatur aus Messungen der Lymphstromstarke und des Eiweisgehaltes der Leberlymphe vor und wahrend einer Gallenstauung auf einen Ruckflus der fortlaufenden produzierten Galle in die Leberlymphe von ca. 7–10% geschlossen werden. 3. In Ruckflusversuchen an unterkuhlten Ratten mit Ringerlosung, die Evansblue enthielt, ergaben Analysen von Blut und Leberlymphe einen Anteil des Ruckflusses in diese Lymphe von ca. 13%.
Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
2021
AIMS We report the 2-year outcomes of the MitrAl ValvE RepaIr Clinical (MAVERIC) trial. Functional mitral regurgitation (FMR) is associated with poor outcomes for which there remains an unmet clinical need. ARTO is a transcatheter annular reduction device for the treatment of FMR and an emerging alternative for patients at high surgical risk. The MAVERIC trial was designed to evaluate the safety and performance of the ARTO system in FMR and heart failure (HF). METHODS AND RESULTS MAVERIC is an international multicentre, prospective, single arm study enrolling patients with FMR grade ≥ 2, New York Heart Association (NYHA) class ≥II symptoms despite maximal medical therapy. Patients were excl…
Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?
2016
Transcatheter edge-to-edge repair for tricuspid regurgitation in Barlow-type tricuspid valve prolapse
2020
Early symptomatic benefit indicates long-term prognosis after transcatheter mitral valve edge-to-edge repair in functional and degenerative etiology
2021
Mitral regurgitation (MR) is common in patients with heart failure and constitutes an independent risk factor for adverse prognosis besides NYHA-class. The predictive value of dyspnea reduction after transcatheter mitral valve repair (TMVr) on outcome has not been investigated up to now.We enrolled 627 consecutive patients (47.0% female, 57.4% functional MR; median follow-up 486 days[IQR 157/961]; survival status available in 96.8%; symptoms assessed in n = 556 at baseline / n = 406 at 1 month) treated with isolated percutaneous mitral valve edge-to-edge repair in our center from 06/2010-03/2018 (exclusion of combined forms of TMVr) in a monocentric retrospective analysis. Survival was 97.6…
Preoperative evaluation before MitraClip®: present and future perspective.
2014
ABSTRACT Mitral regurgitation (MR) is the second most common heart valve disease worldwide. Currently, the management of MR is based on medical therapy (including biventricular pacing), surgery (mitral valve replacement or repair) and percutaneous therapy. However, in spite of guideline recommendations, 50% of individuals assessed in the Euro Heart Survey were not referred to surgical intervention due to comorbidities or real or perceived high risks for cardiac surgery; thus, in recent years, the focus of research has shifted to the development of percutaneous approaches to treat severe MR in order to restore valve function in a minimally invasive fashion. Among these techniques, the perc…
Preliminary Short-term Results of a Population of Patients Treated with MitraClip therapy: one Center Experience
2017
<p><span>Objectives: This retrospective analysis sought to evaluate 1-month outcomes and therapy effectiveness of a population of patients treated with MitraClip therapy. We describe in this article the preliminary results of primary effictiveness endpoint.</span></p><p><span>Background: Percutaneous Mitral Repair is being developed to treat severe mitral regurgitation (MR),with increasing real-world cases of functional MR(FMR). In the EVEREST(Endovascular Valve Edge-to-Edge Repair Study)II trial,percutaneous device showed superior safety but less reduction in MR at 1year. 4-year outcomes from EVEREST II trial showed no difference in the prevalence of mod…